Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
Jason J. Luke(University of Chicago), Aung Naing(The University of Texas MD Anderson Cancer Center), Johanna C. Bendell(Dana-Farber Cancer Institute), Razelle Kurzrock(Medical College of Wisconsin), Charles Schneider(University of Pennsylvania), Marwan Fakih(City of Hope), Sarah P. Blagden(Churchill Hospital), Irene Braña(Vall d'Hebron Institute of Oncology), Ryan Geschwindt(Incyte (United States)), Kevin O’Hayer(Incyte (United States)), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Laura W. Goff(Vanderbilt University Medical Center), Feng Zhou(Nanchang University), Michael Smith(Incyte (United States)), E. Gabriela Chiorean(University of Washington)
Cited by 30
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k